Epidemiology and diagnostic tools to detect and diagnose prostate cancer

One of the cancers that affects men and has a major impact on the rising death rates among men worldwide is prostate cancer. Prostate cancer patients may have localized or advanced disease at presentation. Our goal in this study is to present a comprehensive picture of prostate cancer, covering its epidemiology and several diagnostic techniques. Prostate-specific antigen (PSA) testing, transrectal ultrasound (TRUS), magnetic resonance imaging (MRI), prostate biopsy, Positron emission tomography (PET) scan, risk stratification bioassay test, germline testing, digital rectal exam (DRE), and single-cell RNA-sequencing (scRNA-seq) were among the techniques we covered. For clinical and patient care, prostate cancer (PCa) diagnosis and appropriate staging are essential. Thanks to extensive medical research and development, sensitive and advanced diagnostic instruments are now available. Prostate-specific antigen (PSA) blood testing and rectal examination continue to be the mainstays of screening, while multiparametric magnetic resonance imaging (mpMRI) is used for local staging. In order to better detect clinically significant PCa and identify patients who need targeted biopsies, recent developments in mpMRI, PET, and MRI have led to standardized interpretation and greater prescription by doctors. Other types that are becoming increasingly important, particularly to identify the recurrent rate of cancer, include germline testing, risk stratification bioassay testing, and single-cell RNA-sequencing (scRNA-seq). The combined use of these technologies will assist patients and clinicians in selecting the most suitable and individualized course of treatment for this highly variable condition and also make early diagnosis achievable.